Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Basel, 1. April 2015 - Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass sie eine Lizenzvereinbarung über neuartige panRAF-Kinase-Inhibitoren abgeschlossenen hat. Lizenzgeber ist ein...
-
Basel, Switzerland, April 1, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that it has entered into a license agreement for novel panRAF kinase inhibitors with a consortium of...
-
VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 20, 2015) - Levon Resources Ltd. ("Levon") (TSX:LVN)(OTCQX:LVNVF)(BERLIN:LO9)(FRANKFURT:LO9) and SciVac Ltd. ("SciVac") announced today...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Press ReleaseLausanne, 13 March 2015 ...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Communiqué de presse ...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Press...
-
TORONTO, ONTARIO--(Marketwired - March 9, 2015) - Rodinia Lithium Inc. ("Rodinia" or the "Company") (TSX VENTURE:RM), has entered into a definitive sale agreement with a private Argentine...
-
Basel, 6. März 2015 - Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass die US-amerikanische Arzneimittelbehörde Food and Drug Administration (FDA) Isavuconazol für die Behandlung von...
-
Basel, Switzerland, March 6, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) approved Astellas' New Drug Application (NDA) for the...
-
VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 2, 2015) - Levon Resources Ltd. ("Levon" or the "Company") (TSX:LVN)(OTCQX:LVNVF)(BERLIN:LO9)(FRANKFURT:LO9) is issuing this press...